​

Castle Biosciences (CSTL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CSTL Stock Forecast

Castle Biosciences (CSTL) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $38.75, with a high of $44.00 and a low of $35.00. This represents a 16.75% increase from the last price of $33.19.

$20 $25 $30 $35 $40 $45 High: $44 Avg: $38.75 Low: $35 Last Closed Price: $33.19

CSTL Stock Rating

Castle Biosciences stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 11 Strong Sell Sell Hold Buy Strong Buy

CSTL Price Target Upside V Benchmarks

TypeNameUpside
StockCastle Biosciences16.75%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks1.69%

Price Target Trends

1M3M12M
# Anlaysts-211
Avg Price Target-$40.00$44.27
Last Closing Price$33.19$33.19$33.19
Upside/Downside-20.52%33.38%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26-9---9
Sep, 26-9---9
Aug, 26-9---9
Jul, 26-9---9
Jun, 26-8---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 03, 2026Sung Ji NamBTIG$44.00$28.0057.14%32.57%
Jul 31, 2026Robert W. Baird$36.00$26.7934.38%8.47%
Jun 24, 2026Roth Capital$40.00$22.1280.83%20.52%
May 29, 2026KeyBanc$35.00$21.1965.17%5.45%
Apr 20, 2026Kyle MiksonCanaccord Genuity$40.00$25.0459.74%20.52%
Jan 29, 2026Paul KnightKeyBanc$50.00$39.1627.68%50.65%
Jan 26, 2026Subbu NambiGuggenheim$47.00$43.089.10%41.61%
Jan 12, 2026Lake Street$52.00$40.1429.55%56.67%
Jan 05, 2026Guggenheim$43.00$37.7713.85%29.56%
Dec 22, 2025Canaccord Genuity$50.00$39.4426.77%50.65%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 03, 2026BTIGBuyBuyhold
Jun 24, 2026Roth CapitalBuyinitialise
Mar 02, 2026Morgan StanleyBuyupgrade
Jan 29, 2026KeyBancOverweightOverweighthold
Jan 26, 2026GuggenheimBuyBuyhold
Jan 12, 2026Lake StreetBuyBuyhold
Jan 05, 2026GuggenheimBuyBuyhold
Dec 12, 2025BTIGBuyBuyhold
Nov 04, 2025BTIGBuyBuyhold
Mar 28, 2025GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.24$-2.58$-2.14$0.66$-0.83---
Avg Forecast$-1.46$-2.72$-2.60$0.39$-1.79$-1.38$-1.22$-0.18
High Forecast$-1.40$-2.65$-2.34$0.42$-1.22$-0.40$-0.28$-0.17
Low Forecast$-1.51$-2.84$-2.86$0.35$-2.35$-2.54$-2.29$-0.19
Surprise %-15.07%-5.15%-17.69%69.23%-53.63%---

Revenue Forecast

$50M $120M $190M $260M $330M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$94.08M$137.04M$219.79M$332.07M$344.23M---
Avg Forecast$92.78M$135.89M$209.95M$327.49M$274.08M$304.02M$325.14M$367.70M
High Forecast$95.23M$140.49M$215.07M$345.82M$289.42M$309.11M$325.14M$388.28M
Low Forecast$90.12M$132.96M$204.83M$318.47M$266.53M$298.94M$325.14M$357.57M
Surprise %1.41%0.84%4.69%1.40%25.59%---

Net Income Forecast

$-70M $-52M $-34M $-16M $2M $20M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-31.29M$-67.14M$-57.47M$18.25M$-24.16M---
Avg Forecast$-30.90M$-45.27M$-57.47M$10.37M$-50.49M$-35.73M$-21.80M$-4.69M
High Forecast$-24.72M$-36.21M$-45.97M$11.31M$-32.66M$-10.78M$-7.50M$-4.52M
Low Forecast$-37.07M$-54.32M$-68.96M$9.42M$-63.08M$-68.20M$-61.38M$-5.03M
Surprise %1.28%48.31%-75.98%-52.15%---

CSTL Forecast FAQ

Is Castle Biosciences stock a buy?

Castle Biosciences stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Castle Biosciences is a favorable investment for most analysts.

What is Castle Biosciences's price target?

Castle Biosciences's price target, set by 11 Wall Street analysts, averages $38.75 over the next 12 months. The price target range spans from $35 at the low end to $44 at the high end, suggesting a potential 16.75% change from the previous closing price of $33.19.

How does Castle Biosciences stock forecast compare to its benchmarks?

Castle Biosciences's stock forecast shows a 16.75% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the diagnostics & research stocks industry (1.69%).

What is the breakdown of analyst ratings for Castle Biosciences over the past three months?

  • October 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Castle Biosciences’s EPS forecast?

Castle Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.38, marking a 66.27% increase from the reported $-0.83 in 2025. Estimates for the following years are $-1.22 in 2027, and $-0.18 in 2028.

What is Castle Biosciences’s revenue forecast?

Castle Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $304.02M, reflecting a -11.68% decrease from the reported $344.23M in 2025. The forecast for 2027 is $325.14M, and $367.7M for 2028.

What is Castle Biosciences’s net income forecast?

Castle Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-35.725M, representing an 47.88% increase from the reported $-24.158M in 2025. Projections indicate $-21.8M in 2027, and $-4.69M in 2028.